A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Phase 2 Recruiting
20 enrolled
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 2/3 Recruiting
660 enrolled
ALLO-T-DART
Phase 1 Recruiting
30 enrolled
MagnetisMM-6
Phase 3 Recruiting
1,116 enrolled
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 Recruiting
150 enrolled
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Phase 3 Recruiting
570 enrolled
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
MajesTEC-7
Phase 3 Recruiting
1,590 enrolled
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1 Recruiting
140 enrolled
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 Recruiting
288 enrolled
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 Recruiting
1,450 enrolled
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Phase 2 Recruiting
20 enrolled
ElLen
Phase 3 Recruiting
824 enrolled
Pan Tumor Rollover Study
Phase 2 Recruiting
1,500 enrolled
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Phase 2 Recruiting
96 enrolled
MAGNETISMM-5
Phase 3 Recruiting
944 enrolled
iMMagine-3
Phase 3 Recruiting
450 enrolled
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Phase 3 Recruiting
1,000 enrolled
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 Recruiting
358 enrolled